



City of Cambridge

R-95.

IN CITY COUNCIL

September 10, 2001

COUNCILLOR SULLIVAN
COUNCILLOR BORN
COUNCILLOR BRAUDE
COUNCILLOR DAVIS
COUNCILLOR DECKER
MAYOR GALLUCCIO
VICE MAYOR MAHER
COUNCILLOR REEVES
COUNCILLOR TOOMEY

WHEREAS: Biopure Corporation, a Cambridge company, has developed Hemopure, a blood substitute; and

WHEREAS: Biopure was in competition with three other companies for development of a blood substitute; and

WHEREAS: Hemopure has undergone nine years of clinical testing; and

WHEREAS: With the shortage of blood supplies, Hemopure is a much needed, life saving product; now therefore be it

RESOLVED: That this City Council go on record extending its congratulations to Biopure Corporation on the development of its new product Hemopure; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Biopure Corporation on behalf of the entire City Council.

In City Council September 10, 2001.

Adopted by the affirmative vote of nine members.

Attest:- D. Margaret Drury, City Clerk.

A true copy;

ATTEST:-

A handwritten signature in cursive script, reading "D. Margaret Drury".

D. Margaret Drury
City Clerk

Councillor Sullivan

295.

Whereas: Biopure Corp, a Cambridge company, has developed Hemopure, a blood substitute; and

Whereas: Biopure was in competition with 3 other companies for development of a blood substitute; &

Whereas: Hemopure, has undergone 9 yrs of ~~clinical~~ clinical testing; ~~and~~ &

Whereas: With the shortage of blood supplies Hemopure is a much needed, life saving product; now therefore be it

Resolved: That this City Council go on record extending its congratulations to Biopure Corporation on the development of its new product, Hemopure; & be it further

Resolved SEC TO Biopure Corp

To Paula

From Michael

Date August 28, 2001

Re ORDERS

Hi Paula

Please put orders in on the following for me.

- (1) On the death of Joseph Downes
Boston Globe 8/28
Fitzgerald
- (2) On the death of Cothern
Boston Globe 8/28
- (3) On the death of William H. King Jr
Boston Globe 8/28
- (4) Obituary to Biopure
Boston Globe 8/28
Business Section D.1

Thanks

Michael

The US dollar
1.0971 euro ▲
0.0013

10-year Treasury
4.94% ▲ 0.03

Bloomberg
Mass. index
218.18 ▲ 0.54

Microsoft Corp. will delay the launch of its video-game console in Japan until Feb. 22, missing the holiday shopping season, to focus on US game operations. The largest software maker had planned to introduce its first game console in Japan by the end of the year. **D2**

Deere & Co. plans to sell its money-losing Homelite landscaping-products business and reorganize its construction and forestry division to cut about 2,000 jobs, or about 4.6 percent of its payroll. **D2**



Biopure shares soar 23% on trial results

Firm says tests show blood substitute's safe

By Naomi Aoki
GLOBE STAFF

Biopure Corp. yesterday said studies show that its blood substitute, Hemopure, is as safe as transfusions of human blood, surmounting a major obstacle as the Cambridge company seeks to become the first to market such an alterna-

tive in the United States.

Shares in Biopure shot up 23 percent, or \$4.65, yesterday on the news, closing at \$24.55 in trading on the Nasdaq Stock Market. In the past year, as the company completed its final round of human clinical testing and began releasing study results, the stock has climbed more than 50 percent.

Biopure released data in May showing that Hemopure reduced or eliminated the need for blood transfusions in 95 percent of patients. But doctors and in-

vestors remained skeptical about Hemopure's prospects for US approval because of a history of high-profile failures in the effort to develop a safe alternative to donated human blood.

"It's a real win," said Carl Rausch, Biopure's chairman and chief executive. "We've really had to work hard, and to have this win is a very significant event. When I told the company this morning, I was speechless for the first time in my life."

Biopure has emerged as the sole com-

pany in what has turned out to be a grueling marathon to complete clinical studies for US approval. It became the world's first and only supplier of a blood substitute in April when it won approval to market Hemopure in South Africa. If all goes as planned, Biopure will mark another first later this year when it submits its application to the US Food and Drug Administration. It expects to file an application with European regulatory authorities next year.

BIOPURE, Page D5

Supplies and demand

Pens

Rollerball • Ballpoint • Gels

Hot Colors!

Gels • Glitter • Fluorescents



Nasdaq
9,912.41

and news:
on.com/business

SYRE &
STEIN

Capital

sales
fund
time

Boston mutual
inner earn an 86
stors over the last
n this dismal mar-

ldn't. But
ed CGM Focus
out the lights
argely because it is
Boston authorized
ell as buy them.
3.9 percent in
rd & Poor's 500 in
d the fund is up
r this year.

ounted for about
nillion CGM Fo-
30, according to a
ut at one point
60 percent of the
ie short portfolio
ains substan-
telecommunica-

wiring residences in Greater Boston, would decline in value.

Those holders were already big

Nasdaq-listed stocks continued to rise to record levels. Short interest, measured through mid-August, had risen 1.2 percent in a month

Corp. Lopardo, a periodic seller of State Street stock, most recently unloaded 15,000 shares in April, prior to a 2-for-1 split. At the time

Steven Syre (617-929-2918) and Charles Stein (617-929-2922) can be reached by e-mail at boscapp@globe.com.

Biopure stock soars as studies show Hemopure's safe

► **BIOPURE**
Continued from Page D1

The early front-runner in the 20-year race, Baxter International, was forced to abandon development of its product after safety concerns arose during clinical trials. Northfield Laboratories, once seen as having a lead over Biopure, has also fallen behind. Biopure's closest competitor, Canada's Hemosol Inc., suffered a setback earlier this month when the FDA asked for changes in the company's clinical studies, delaying their completion indefinitely.

Biopure's Hemopure, made from cow's blood, has undergone

nine years of clinical trials in the United States, South Africa, and Canada. In the final phase of testing, 350 patients undergoing orthopedic surgery were given Hemopure, and compared to 338 patients given human blood transfusions. Analyses of the data showed that the overall medical risk to patients receiving Hemopure was no worse than for those receiving blood, Biopure said. The company looked at the patients' vital signs, neurological exams, and electrocardiogram results.

Blood substitutes like Hemopure could ease the strain on the world's overtaxed blood banks at a

time when concerns about the transmission of mad-cow disease, HIV, and other ailments are further decreasing the availability of donors.

Because red-blood cells carry oxygen, a significant loss of blood can threaten a person's life by cutting off the body's oxygen supply. Although Hemopure does not replace red blood cells, it does help carry oxygen. Unlike blood, which has a shelf life of 42 days, Hemopure can be kept without refrigeration for about three years. It can also be given to patients of all blood types.

The US blood supply is chron-

ically low. Nationwide, the American Red Cross collected 6.4 million donations of blood last fiscal year, and shortages have been growing the past few years. Less than 5 percent of eligible Americans donate blood.

It supplies hospitals in Massachusetts, Maine, Vermont, and New Hampshire with more than 350,000 units of blood each year. "This solves a real need in caring for patients, not just in the United States but around the world," Rausch said.

Naomi Aoki can be reached by e-mail at naoki@globe.com.

INFORMATION

**BOSTON
UNIVERSITY
PROGRAM FOR
FINANCIAL
PLANNERS**

Extend your Mind . . .

Extend your Skills . . .

Extend your Career . . .

CALL 617/353-4497 FOR M

CHARLES I
Thursday, S

College o
871 Com
BU West sto

BRAINTREE
Wednesday,

South Shc
25 Braintr
At the junctio

Classes

e-mail: spas@www.bu.edu

An equal opportunity
affirmative action institution



City of Cambridge

R-95.

IN CITY COUNCIL

September 10, 2001

COUNCILLOR SULLIVAN

WHEREAS: Biopure Corporation, a Cambridge company, has developed Hemopure, a blood substitute; and

WHEREAS: Biopure was in competition with three other companies for development of a blood substitute; and

WHEREAS: Hemopure has undergone nine years of clinical testing; and

WHEREAS: With the shortage of blood supplies, Hemopure is a much needed, life saving product; now therefore be it

RESOLVED: That this City Council go on record extending its congratulations to Biopure Corporation on the development of its new product Hemopure; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Biopure Corporation on behalf of the entire City Council.

1240R

Resolution #95

Congratulations to Biopure Corporation, a Cambridge company, on the development of its new product, Hemopure, a blood substitute.

Councillor Sullivan

In City Council September 10, 2001

ORDER ADOPTED